Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation - - VRDN-001 10mg/kg proof of concept...
Clinical Trial
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today...
Pasithea Therapeutics Acquires AlloMek Therapeutics
-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application...
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs
Accomplished industry leader with over twenty years of experience building lasting relationships with global regulatory agencies and guidance in the...
Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and...
Synthetic Biologics Rebrands as Theriva Biologics
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administrationROCKVILLE, Md., Oct. 12, 2022...
Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.
Estimated Over 1.4 Million Americans Suffer from LBD – Often Misdiagnosed – No Approved TreatmentsPURCHASE, N.Y., Oct. 12, 2022 (GLOBE...
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
NORCROSS, Ga., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022Study expected to assess VBI-1901...
PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022
FLORHAM PARK, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month
The sweepstakes aims to raise awareness of Deep TMS™ as a treatment option for mental health disorders so patients #DontMissAnotherMoment...
Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022
-- Approximately 100 European health care professionals invited to discuss recent scientific developments in rare pathway-related obesities -- -- Rhythm...
Microbot Medical Enhances Strategic Focus on its Endovascular Solutions
Suspending Development of SCS and Evaluating Alternatives for SCS AssetsHINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc....
Optimi Health Announces Closing of Strategic Non-Brokered Private Placement
Chip Wilson expands current share position and commits gross proceeds of up to $3.27 millionNOT FOR DISTRIBUTION TO U.S. NEWSWIRE...
Cannabix Technologies to Participate in October Southern US Study using Marijuana Breathalyzer Technology
Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety Cannabix October...
SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Tarsus Announces Transition Plans for Board of Directors
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and...
SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is...